TTE Improves Clinical Management of Stable Chest Pain

Recruiting

• Conditions: Transthorcic Echocardiography; Stable Angina Pectoris; Coronary Artery Disease; Major Adverse Cardiac Events; Invasive Coronary Angiography

• Registration Number: NCT07063147
• Lead Sponsor: Tianjin Chest Hospital

Brief Summary

The investigator aims to prospectively enroll patients who were referred for transthorcic echocardiography (TTE) for the assessment of stable chest pain (SCP) suspected of obstructive coronary artery disease (CAD). All patients underwent TTE according to established guidelines and local institutional protocols. This study will determine if TTE-based imaging evaluation can provide more informaton to improve clinical management for SCP, including fewer MACE and better decision-making of downstream investigations and therapeutic interventions.

Detailed Description

Not available

Study Timeline

• Study Start: 2025-01-01
• Status Verified: 2025-07
• Study First Submitted: 2025-07-03
• Study First Submitted QC: 2025-07-03
• Study First Posted: 2025-07-14
• Last Update Submitted: 2025-07-15
• Last Update Posted: 2025-07-18
• Primary Completion: 2030-12-31
• Study Completion: 2040-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 50000

Inclusion Criteria

• symptomatic patients with SCP suspected of obstructive CAD.
• referred for TTE for the assessment of SCP.
• ≥18 years of age.
• signed informed consent.

Exclusion Criteria

• acute coronary syndromes
• previous CAD or coronary revascularization
• nonsinus rhythm
• cardiomyopathy, valvular disease, congenital heart disease or left cardiac insufficiency because of other reasons

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Major adverse cardiovascular events	10 years

Secondary Outcome Measures

Name	Time	Method
Invasive coronary angiography	10 years	Invasive coronary angiography occurred at follow-up after TTE, attributed to TTE results or unplanned.
Medication prescription	10 years	Change for medication prescription of antiplatelet agents, anti-ischemic drugs, lipid-lowering agents, angiotensin-converting enzyme inhibition and so on, attributed to TTE results or unplanned,
Coronary revascularization	10 years	PTCA, PCI or CABG occurred at follow-up after TTE, attributed to TTE results or unplanned.

Trial Locations

Locations (1)

Tianjin Chest Hospital; 🇨🇳 Tianjin, China